

PROMOTING RECOGNITION, DIAGNOSIS AND TREATMENT OF COLD AGGLUTININ DISEASE



RESOURCES

CADENCE Registry

<https://coldagglutininnews.com/2021/01/07/cadence-registry>

Cold Agglutinin Disease Newsletter:

<https://coldagglutininnews.com>

NORD Rare Diseases Database, Cold Agglutinin Disease

<https://rarediseases.org/rare-diseases/cold-agglutinin-disease/>

REFERENCES

(full reference list from the program)

Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. *Dis Markers*. 2015;2015:635670. doi:10.1155/2015/635670

Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New insights in autoimmune hemolytic anemia: From pathogenesis to therapy stage 1. *J Clin Med*. 2020;9(12):3859. doi:10.3390/jcm9123859

Berentsen S. How I manage patients with cold agglutinin disease. *Br J Haematol*. 2018;181(3):320-330. doi:10.1111/bjh.15109

Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. *Front Immunol*. 2020;11:590. doi:10.3389/fimmu.2020.00590

Berentsen S, Barcellini W, D'Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. *Blood*. 2020;136(4):480-488. doi:10.1182/blood.2020005674

Berentsen S, Beiske K, Tjønnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. *Hematology*. 2007;12(5):361-70. doi:10.1080/10245330701445392

Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. *Blood*. 2017;130(4):537-541. doi:10.1182/blood-2017-04-778175

Berentsen S, Randen U, Tjønnfjord GE. Cold agglutinin-mediated autoimmune hemolytic anemia. *Hematol Oncol Clin North Am*. 2015;29(3):455-71. doi:10.1016/j.hoc.2015.01.002

Bylsma LC, Gulbech-Ording A, Rosenthal A, et al. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. *Blood Adv*. 2019;3(20):2980-2985. doi:10.1182/bloodadvances.2019000476

Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. *Res Pract Thromb Haemost*. 2020;4(4):628-635. doi:10.1002/rth2.12333

ClinicalTrials.gov. A study to assess the efficacy and safety of BIVV009 (sutimlimab) in participants with primary cold agglutinin disease without arecent history of blood transfusion (Cadenza). Last update posted: September 3, 2020. Available at <https://clinicaltrials.gov/ct2/show/NCT03347422>.

PROMOTING RECOGNITION, DIAGNOSIS AND TREATMENT OF COLD AGGLUTININ DISEASE



ClinicalTrials.gov. Safety and tolerability study in adults with cold agglutinin disease previously treated with BIVV020. Last update posted: July 20, 2021. Available at <https://clinicaltrials.gov/ct2/show/NCT04802057>.

ClinicalTrials.gov. A safety and tolerability study of BIVV020 in adults with cold agglutinin disease. Last update posted: June 30, 2021. Available at <https://clinicaltrials.gov/ct2/show/NCT04269551>.

Gertz MA. Management of cold haemolytic syndrome. *Br J Haematol*. 2007;138(4):422-9. doi:10.1111/j.1365-2141.2007.06664.x

Hill QA, Puneekar R, Arian JM, Broome CM, Su J. Mortality among patients with cold agglutinin disease in the United States: an electronic health record (EHR)-based analysis. *Blood*. 2019;134(suppl 1):4790. doi:10.1182/blood-2019-122140

Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. *Blood Rev*. 2020;41:100648. doi:10.1016/j.blre.2019.100648

Jäger U, D'Sa S, Schörghenhofer C, et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. *Blood*. 2019;133(9):893-901. doi:10.1182/blood-2018-06-856930

Jeskowiak A, Goerge T. Images in clinical medicine. Cutaneous necrosis associated with cold agglutinins. *N Engl J Med*. 2013;369(1):e1. doi:10.1056/NEJMicm1212538

Kohlert S, McLean L, Scarvelis D, Thompson C. A case report of severe nasal ischemia from cold agglutinin disease and a novel treatment protocol including HBOT. *J Otolaryngol Head Neck Surg*. 2019;48(1):52. doi:10.1186/s40463-019-0369-0

Natsuaki M, Morimoto T, Yamaji K, et al; CREDO-Kyoto PCI/CABG Registry Cohort 2, RESET, and NEXT trial investigators. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores. *J Am Heart Assoc*. 2018;7(11):e008708. doi:10.1161/JAHA.118.008708

Onishi S, Ichiba T, Miyoshi N, Nagata T, Naito H. Unusual underlying disorder for pulmonary embolism: Cold agglutinin disease. *J Cardiol Cases*. 2016;15(2):43-45. doi:10.1016/j.jccase.2016.10.005

Pérez-Lamas L, Moreno-Jiménez G, Tenorio-Núñez MC, et al. Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease. *Am J Hematol*. 2021;96(8):E288-E291. doi:10.1002/ajh.26214

Petz LD. Cold antibody autoimmune hemolytic anemias. *Blood Rev*. 2008;22(1):1-15. doi:10.1016/j.blre.2007.08.002

Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. *Blood*. 2018;132(5):547-550. doi:10.1182/blood-2018-03-835413

Röth A. Do temperature and time matter in coldagglutinin disease? *Blood*. 2020;136(4):380-381. doi:10.1182/blood.202006566

Röth A. Presented at late-breaking abstract "Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): Results from the phase 3 Cardinal Study long-term follow-up." Oral and Poster Abstracts at 61st American Society of Hematology Annual Meeting, Dec 2019. Orlando, FL. Available at <https://ash.confex.com/ash/2020/webprogram/Paper138909.html>.

PROMOTING RECOGNITION, DIAGNOSIS AND TREATMENT OF COLD AGGLUTININ DISEASE



Röth A, Barcellini W, D'Sa S, et al. Sutimlimab in coldagglutinin disease. *N Engl J Med.* 2021;384(14):1323-1334. doi:10.1056/NEJMoa2027760

Röth A, Bommer M, Hüttmann A, et al. Eculizumab in coldagglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. *Blood Adv.* 2018;2(19):2543-2549. doi:10.1182/bloodadvances.2018024190

Röth A, Dührsen U. Cold agglutinin disease. *Eur J Haematol.* 2010;84(1):91. doi:10.1111/j.1600-0609.2009.01320.x

Sharma K, Patel A. Livedo reticularis in cold agglutinin disease. *N Engl J Med.* 2019;381(13):e27. doi:10.1056/NEJMicm1902289

Wouters D, Zeerleder S. Complement inhibitors to treat IgM-mediated autoimmune hemolysis. *Haematologica.* 2015;100(11):1388-95. doi:10.3324/haematol.2015.128538

Zaninoni A, Giannotta JA, Galli A, et al. The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease. *Front Immunol.* 2021;12:649441. doi:10.3389/fimmu.2021.649441